10 Best High Quality Growth Stocks At 52w High for November 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The current market environment is characterized by heightened volatility, sector rotation, and a premium on quality growth stocks. Our selection methodology leverages ValueSense’s proprietary intrinsic value models, quality ratings, and fundamental analysis to identify stocks with robust financials, strong growth trajectories, and attractive valuations. Each pick is screened for high return on invested capital (ROIC), healthy free cash flow, and sector leadership, ensuring a diversified portfolio across technology, healthcare, and industrials[1][2].
Featured Stock Analysis
Alphabet Inc. (GOOG)
| Metric | Value |
|---|---|
| Market Cap | $3,398.5B |
| Quality Rating | 8.0 |
| Intrinsic Value | $236.2 |
| 1Y Return | 63.6% |
| Revenue | $385.5B |
| Free Cash Flow | $73.6B |
| Revenue Growth | 13.5% |
| FCF margin | 19.1% |
| Gross margin | 59.2% |
| ROIC | 31.4% |
| Total Debt to Equity | 8.7% |
Investment Thesis
Alphabet Inc. stands as a dominant force in global technology, driven by its core search, advertising, and cloud businesses. With a market cap of $3,398.5B and a quality rating of 8.0, Alphabet’s consistent revenue growth 13.5% and robust free cash flow $73.6B underscore its operational excellence. The company’s intrinsic value of $236.2 suggests continued upside, supported by a 1-year return of 63.6%. Alphabet’s gross margin of 59.2% and ROIC of 31.4% reflect superior profitability and capital efficiency.
Key Catalysts
- Expansion in cloud computing and AI services
- Strong advertising revenue growth
- Ongoing innovation in hardware and software ecosystems
- Strategic investments in emerging technologies
Risk Factors
- Regulatory scrutiny and antitrust actions
- Dependence on advertising for revenue
- Competitive pressures from other tech giants
- Currency fluctuations impacting global operations
Alphabet Inc. (GOOGL)
| Metric | Value |
|---|---|
| Market Cap | $3,398.5B |
| Quality Rating | 8.0 |
| Intrinsic Value | $241.4 |
| 1Y Return | 64.9% |
| Revenue | $385.5B |
| Free Cash Flow | $73.6B |
| Revenue Growth | 13.4% |
| FCF margin | 19.1% |
| Gross margin | 59.2% |
| ROIC | 31.4% |
| Total Debt to Equity | 8.7% |
Investment Thesis
GOOGL shares represent the same underlying business as GOOG, with minor voting rights differences. The financial profile mirrors GOOG: $3,398.5B market cap, 8.0 quality rating, and $385.5B in revenue. The intrinsic value is slightly higher at $241.4, and the 1-year return is 64.9%. Alphabet’s diversified revenue streams and high gross margin 59.2% position it as a resilient leader in tech.
Key Catalysts
- Accelerated AI integration across products
- Growth in YouTube and cloud segments
- Expansion into new international markets
- Strategic acquisitions and partnerships
Risk Factors
- Regulatory and legal risks globally
- Shifts in digital advertising trends
- Cybersecurity threats
- Market saturation in core segments
ASML Holding N.V. (ASML)
| Metric | Value |
|---|---|
| Market Cap | $410.6B |
| Quality Rating | 8.0 |
| Intrinsic Value | $861.0 |
| 1Y Return | 57.8% |
| Revenue | €32.2B |
| Free Cash Flow | €8,961.8M |
| Revenue Growth | 22.8% |
| FCF margin | 27.8% |
| Gross margin | 52.7% |
| ROIC | 30.2% |
| Total Debt to Equity | 14.2% |
Investment Thesis
ASML is the world’s leading supplier of photolithography systems for semiconductor manufacturing, with a $410.6B market cap and an 8.0 quality rating. The company’s revenue growth of 22.8% and free cash flow margin of 27.8% highlight its strong financial position. ASML’s intrinsic value of $861.0 and 1-year return of 57.8% reflect investor confidence in its technological leadership and critical role in the global chip supply chain.
Key Catalysts
- Rising demand for advanced semiconductor equipment
- Expansion in EUV technology adoption
- Strategic partnerships with leading chipmakers
- Global chip shortage driving capital investment
Risk Factors
- Cyclical nature of semiconductor industry
- High R&D and capital expenditure requirements
- Geopolitical tensions affecting supply chains
- Currency risk due to euro-denominated revenue
Lam Research Corporation (LRCX)
| Metric | Value |
|---|---|
| Market Cap | $199.1B |
| Quality Rating | 8.2 |
| Intrinsic Value | $136.3 |
| 1Y Return | 113.1% |
| Revenue | $19.6B |
| Free Cash Flow | $5,849.0M |
| Revenue Growth | 25.7% |
| FCF margin | 29.9% |
| Gross margin | 49.3% |
| ROIC | 51.7% |
| Total Debt to Equity | 44.0% |
Investment Thesis
Lam Research is a key player in semiconductor process equipment, boasting a $199.1B market cap and the highest quality rating in this list 8.2. With a 1-year return of 113.1%, Lam’s revenue growth of 25.7% and ROIC of 51.7% signal exceptional operational performance. The intrinsic value is $136.3, and its free cash flow margin stands at 29.9%, indicating strong profitability.
Key Catalysts
- Growth in memory and logic chip demand
- Expansion of fabrication capacity worldwide
- Technological innovation in etch and deposition tools
- Strategic customer relationships
Risk Factors
- Industry cyclicality and capex cycles
- Intense competition from global peers
- Supply chain disruptions
- High debt-to-equity ratio 44.0%
McKesson Corporation (MCK)
| Metric | Value |
|---|---|
| Market Cap | $101.3B |
| Quality Rating | 6.8 |
| Intrinsic Value | $770.7 |
| 1Y Return | 62.4% |
| Revenue | $377.6B |
| Free Cash Flow | $6,325.0M |
| Revenue Growth | 20.3% |
| FCF margin | 1.7% |
| Gross margin | 3.4% |
| ROIC | 23.4% |
| Total Debt to Equity | (1,151.0%) |
Investment Thesis
McKesson is a leading healthcare distributor with a $101.3B market cap and a quality rating of 6.8. The company’s revenue of $377.6B and 1-year return of 62.4% highlight its scale and resilience. McKesson’s intrinsic value is $770.7, and its revenue growth of 20.3% demonstrates solid expansion. However, the free cash flow margin is modest at 1.7%, and the total debt to equity is notably high -1,151.0%.
Key Catalysts
- Expansion in pharmaceutical distribution
- Growth in specialty healthcare services
- Strategic partnerships with healthcare providers
- Adoption of technology in supply chain management
Risk Factors
- High leverage and debt levels
- Regulatory changes in healthcare
- Margin pressure from competition
- Operational risks in distribution
TE Connectivity Ltd. (TEL)
| Metric | Value |
|---|---|
| Market Cap | $72.9B |
| Quality Rating | 7.8 |
| Intrinsic Value | $221.7 |
| 1Y Return | 69.0% |
| Revenue | $17.3B |
| Free Cash Flow | $3,203.0M |
| Revenue Growth | 8.9% |
| FCF margin | 18.6% |
| Gross margin | 35.3% |
| ROIC | 10.9% |
| Total Debt to Equity | 44.7% |
Investment Thesis
TE Connectivity specializes in connectivity and sensor solutions, with a $72.9B market cap and a quality rating of 7.8. The company’s intrinsic value is $221.7, and its 1-year return is 69.0%. TE’s revenue growth of 8.9% and ROIC of 10.9% indicate steady performance, while its free cash flow margin is a healthy 18.6%.
Key Catalysts
- Growth in automotive and industrial connectivity
- Expansion into IoT and smart devices
- Innovation in sensor technologies
- Diversification across end markets
Risk Factors
- Exposure to cyclical industries
- Competitive pressures in electronics
- Supply chain constraints
- Moderate debt-to-equity ratio 44.7%
Seagate Technology Holdings plc (STX)
| Metric | Value |
|---|---|
| Market Cap | $54.5B |
| Quality Rating | 7.2 |
| Intrinsic Value | $104.2 |
| 1Y Return | 156.8% |
| Revenue | $9,558.0M |
| Free Cash Flow | $1,218.0M |
| Revenue Growth | 31.6% |
| FCF margin | 12.7% |
| Gross margin | 36.9% |
| ROIC | 55.2% |
| Total Debt to Equity | (7,927.0%) |
Investment Thesis
Seagate is a global leader in data storage solutions, with a $54.5B market cap and a quality rating of 7.2. The company’s 1-year return is an impressive 156.8%, supported by revenue growth of 31.6%. Seagate’s intrinsic value is $104.2, and its ROIC is a standout 55.2%. However, the total debt to equity is extremely high -7,927.0%, and the free cash flow margin is 12.7%.
Key Catalysts
- Rising demand for cloud and enterprise storage
- Innovation in HDD and SSD technologies
- Expansion into edge computing markets
- Strategic partnerships with hyperscale data centers
Risk Factors
- High leverage and debt risk
- Rapid technological change
- Price competition in storage solutions
- Cyclical demand patterns
Cardinal Health, Inc. (CAH)
| Metric | Value |
|---|---|
| Market Cap | $45.4B |
| Quality Rating | 6.9 |
| Intrinsic Value | $208.8 |
| 1Y Return | 76.5% |
| Revenue | $234.3B |
| Free Cash Flow | $4,452.0M |
| Revenue Growth | 4.4% |
| FCF margin | 1.9% |
| Gross margin | 3.7% |
| ROIC | 47.4% |
| Total Debt to Equity | (330.7%) |
Investment Thesis
Cardinal Health is a major healthcare services and products provider, with a $45.4B market cap and a quality rating of 6.9. The company’s intrinsic value is $208.8, and its 1-year return is 76.5%. Cardinal’s revenue growth is modest at 4.4%, and its free cash flow margin is 1.9%. The total debt to equity is high -330.7%, but the ROIC is strong at 47.4%.
Key Catalysts
- Expansion in medical supply distribution
- Growth in specialty healthcare segments
- Strategic partnerships with hospitals and clinics
- Technology adoption in logistics
Risk Factors
- High leverage and debt concerns
- Regulatory risks in healthcare
- Margin compression from competition
- Operational risks in supply chain
Insmed Incorporated (INSM)
| Metric | Value |
|---|---|
| Market Cap | $40.1B |
| Quality Rating | 7.0 |
| Intrinsic Value | $19.4 |
| 1Y Return | 181.8% |
| Revenue | $447.0M |
| Free Cash Flow | ($906.1M) |
| Revenue Growth | 30.3% |
| FCF margin | (202.7%) |
| Gross margin | 69.7% |
| ROIC | (255.1%) |
| Total Debt to Equity | 3.9% |
Investment Thesis
Insmed is a biotechnology company focused on rare diseases, with a $40.1B market cap and a quality rating of 7.0. The company’s intrinsic value is $19.4, and its 1-year return is a remarkable 181.8%. Insmed’s revenue growth is 30.3%, and its gross margin is high at 69.7%. However, the company faces negative free cash flow -$906.1M and ROIC -255.1%, reflecting heavy investment in R&D.
Key Catalysts
- Pipeline of innovative therapies for rare diseases
- Positive clinical trial results
- Strategic partnerships and licensing deals
- Expansion into new markets
Risk Factors
- High cash burn and negative free cash flow
- Regulatory approval risks
- Competitive pressures in biotech
- Volatility in share price
Celestica Inc. (CLS)
| Metric | Value |
|---|---|
| Market Cap | $39.6B |
| Quality Rating | 6.9 |
| Intrinsic Value | $122.9 |
| 1Y Return | 403.6% |
| Revenue | $11.2B |
| Free Cash Flow | $396.9M |
| Revenue Growth | 21.1% |
| FCF margin | 3.5% |
| Gross margin | 11.6% |
| ROIC | 16.8% |
| Total Debt to Equity | 38.7% |
Investment Thesis
Celestica is a global provider of supply chain solutions, with a $39.6B market cap and a quality rating of 6.9. The company’s intrinsic value is $122.9, and its 1-year return is an outstanding 403.6%. Celestica’s revenue growth is 21.1%, and its free cash flow margin is 3.5%. The ROIC is 16.8%, and the total debt to equity is 38.7%.
Key Catalysts
- Growth in electronics manufacturing services
- Expansion into high-value supply chain solutions
- Strategic customer wins
- Diversification across industries
Risk Factors
- Exposure to cyclical demand
- Competitive pressures in EMS
- Supply chain disruptions
- Moderate leverage
Portfolio Diversification Insights
This watchlist achieves sector diversification by balancing technology (Alphabet, ASML, Lam Research, Seagate, Celestica), healthcare (McKesson, Cardinal Health, Insmed), and industrials (TE Connectivity). The inclusion of both large-cap and mid-cap stocks, as well as exposure to growth and defensive sectors, helps mitigate risk and smooth portfolio volatility. High ROIC and free cash flow margins across several picks provide a foundation for long-term capital appreciation.
Market Timing & Entry Strategies
When considering entry points, investors may look for pullbacks from recent highs, confirmation of positive earnings momentum, or sector rotation signals. ValueSense’s intrinsic value models can help identify stocks trading below fair value, while technical charting tools support timing decisions. Staggered entries and dollar-cost averaging can reduce timing risk, especially in volatile markets[2][7].
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected?
Stocks were chosen using ValueSense’s proprietary screening tools, focusing on high quality ratings, strong financial metrics, and attractive intrinsic value scores. The selection process emphasizes diversified sector exposure and robust growth prospects[1][2].
Q2: What's the best stock from this list?
Each stock offers unique strengths; for example, Celestica (CLS) delivered the highest 1-year return 403.6%, while Lam Research (LRCX) boasts the highest quality rating 8.2. The "best" depends on individual investment goals and risk tolerance.
Q3: Should I buy all these stocks or diversify?
Diversification is key to managing risk. This watchlist is designed to provide sector balance, but investors should consider their own portfolio needs and avoid over-concentration in any single sector or stock.
Q4: What are the biggest risks with these picks?
Risks include sector-specific volatility, high leverage (notably in Seagate and McKesson), regulatory changes (especially in healthcare and technology), and cyclical demand patterns. Each stock’s risk profile is detailed in its analysis section.
Q5: When is the best time to invest in these stocks?
Optimal timing may involve waiting for price pullbacks, monitoring earnings releases, or using ValueSense’s intrinsic value signals to identify undervalued entry points. Dollar-cost averaging can help mitigate timing risk in volatile markets[2][7].